Hey @the Zig, if you look at a number of other biotechs on the...

Hey @the Zig, if you look at a number of other biotechs on the ASX they have had a year of positive announcements but no appreciable gain in share price. Most companies have at least halved in this space in 2022. We aren't isolated in this regard.

I do agree ANP has very little interest generally though, volume stays low, positive announcements generate very little moumentum.

I'm not one to advocate the patience approach, this is why I like this new P2B trial design lol. I think this speeds up both partnership opportunity and commercial drug use.